Why Regeneron Is Falling And Why You Should Avoid It

Core Insights - Regeneron Pharmaceuticals (REGN) has been in a downtrend for over 280 days, currently in the 10th Phase of its 18-Phase Adhishthana Cycle, indicating a significant structural breakdown rather than mere technical fluctuations [1][15]. Historical Performance - The current Adhishthana Cycle for Regeneron began on January 29, 2018, with the stock initially following expected market behaviors until Phase 9 [2]. - In Phase 2, Regeneron experienced a strong Rally of Buddhi, surging approximately 113% after a consolidation period of 37 bars [5]. - Phase 3 saw a slight rally followed by a rounded top, leading to a decline of about 33%, aligning with the Adhishthana framework [8]. - Phase 6 established a Nirvana Level at $671.41, which now serves as a valuation benchmark [10]. Phase 9 Breakdown - Phase 9 typically marks a breakout above the bullish "Cakra" channel, but Regeneron broke downwards, leading to a significant decline [13]. - This breakdown triggered the Move of Pralaya, resulting in a collapse of bullish sentiment and a stock price drop of approximately 54% since the break [14]. Future Outlook - Currently in Phase 10, Regeneron is in a state of structural limbo, with no meaningful recovery expected until it enters the Guna Triads (Phases 14, 15, and 16), which begin on February 7, 2028 [15]. - The current structure suggests continued weakness and uncertainty for the stock until the completion of the Guna Triads [15].